Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Completed · Phase 3 · Has a placebo group

Conditions studied: Overactive Bladder

In brief

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

Key facts

Study ID

NCT00444925

Run by

Pfizer

People needed

1712

Starts

2007-04-01

Expected to finish

2008-07-01

Last updated by the study team

2015-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult overactive bladder (OAB) patients who present with OAB symptoms, including urinary frequency >= 8 per day and urgency urinary incontinence >=1 per day

You may not qualify if…

• Patients with conditions that would contraindicate for fesoterodine use, e.g, hypersensitivity to the active substance (fesoterodine) or to peanut or soya or any of the excipients, urinary retention, and gastric retention.
• Patients with significant hepatic and renal disease or other significant unstable diseases.
• OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.

Where it is running

• Pfizer Investigational Site — Huntsville, Alabama, United States
• Pfizer Investigational Site — Mobile, Alabama, United States
• Pfizer Investigational Site — Carmichael, California, United States
• Pfizer Investigational Site — Orangevale, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — Aurora, Colorado, United States
• Pfizer Investigational Site — Waterbury, Connecticut, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Wellington, Florida, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Coeur d'Alene, Idaho, United States
• Pfizer Investigational Site — Sandpoint, Idaho, United States
• Pfizer Investigational Site — Aurora, Illinois, United States
• Pfizer Investigational Site — West Des Moines, Iowa, United States
• Pfizer Investigational Site — Newton, Kansas, United States
• Pfizer Investigational Site — Shrevport, Louisiana, United States
• Pfizer Investigational Site — Watertown, Massachusetts, United States
• Pfizer Investigational Site — Chaska, Minnesota, United States
• Pfizer Investigational Site — Lawrenceville, New Jersey, United States
• Pfizer Investigational Site — Albuquerque, New Mexico, United States
• Pfizer Investigational Site — Garden City, New York, United States
• Pfizer Investigational Site — Mineola, New York, United States
• Pfizer Investigational Site — Burlington, North Carolina, United States
• Pfizer Investigational Site — Concord, North Carolina, United States
• Pfizer Investigational Site — Homewood, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.